{
    "Rank": 1013,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT02718859",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "NK-pancre"
                },
                "Organization": {
                    "OrgFullName": "Fuda Cancer Hospital, Guangzhou",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer",
                "OfficialTitle": "Study of the Combined Therapy of Irreversible Electroporation\uff08IRE\uff09 and Nature Killer (NK) Cells for Advanced Pancreatic Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "March 2019",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 1, 2016",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "March 1, 2017",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "March 1, 2019",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "March 9, 2016",
                "StudyFirstSubmitQCDate": "March 19, 2016",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "March 24, 2016",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "September 10, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 12, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Fuda Cancer Hospital, Guangzhou",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Shenzhen Hank Bioengineering Institute",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporation\uff08IRE\uff09and nature killer(NK) cells for advanced pancreatic cancer.",
                "DetailedDescription": "By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using irreversible electroporation\uff08IRE\uff09and nature killer\uff08NK\uff09 cells for advanced pancreatic cancer.\n\nThe efficacy will be evaluated according to relief degree,progress free survival(PFS) and overall survival(OS).\n\nThe safety will be evaluated by statistics of adverse reaction"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Pancreatic Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "advanced pancreatic cancer",
                        "nature killer cell",
                        "irreversible electroporation"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1",
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "60",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "irreversible electroporation (IRE)",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: irreversible electroporation (IRE )"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "IRE & NK cells",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: NK cells",
                                    "Procedure: irreversible electroporation (IRE )"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "NK cells",
                            "InterventionDescription": "The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "IRE & NK cells"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "irreversible electroporation (IRE )",
                            "InterventionDescription": "The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "IRE & NK cells",
                                    "irreversible electroporation (IRE)"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Relief degree",
                            "PrimaryOutcomeDescription": "It will be evaluated by the Response Evaluation Criteria in Solid Tumors\uff08RECIST\uff09",
                            "PrimaryOutcomeTimeFrame": "1 year"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Progress free survival\uff08PFS\uff09",
                            "SecondaryOutcomeTimeFrame": "1 year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall survival\uff08OS\uff09",
                            "SecondaryOutcomeTimeFrame": "3 year"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAge:18-80\nDiagnosis\uff1aadvanced and active pancreatic cancer\nThe tumour is measurable\nEastern Cooperative Oncology Group(ECOG) score\uff1a0~2\uff1b3 but has no relationship with tumour\n\nVital organ function is normal:\n\ntotal bilirubin(TB) <68\u03bcmol/L aspartate aminotransferase(AST)<90 IU/L Cre<353\u03bcmol/L white blood cell count(WBC)<9\u00d710^9/L,when WBC is close to or even greater than 9\u00d710^9/L\uff0cthe recommended dose should be halved platelet count(PLT)>80\u00d710^9/L Red blood cell specific volume(HCT)>0.20 Non severe viral or bacterial infection\n\nNon pregnant and lactating patients\nNon allergic reactions to biological products\nInformed and consent\n\nExclusion Criteria:\n\nPatients with cardiac pacemaker\nPatients with severe cardiac and pulmonary dysfunction\nPatients that the researchers do not think fit into the group,including patients failed in compliance assessment",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "80 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Lizhi Niu, PhD",
                            "OverallOfficialAffiliation": "Fuda Cancer Hospital",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Central laboratory in Fuda cancer hospital",
                            "LocationCity": "Guangzhou",
                            "LocationState": "Guangdong",
                            "LocationZip": "510000",
                            "LocationCountry": "China"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000010190",
                            "ConditionMeshTerm": "Pancreatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004701",
                            "ConditionAncestorTerm": "Endocrine Gland Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000010182",
                            "ConditionAncestorTerm": "Pancreatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004700",
                            "ConditionAncestorTerm": "Endocrine System Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M12800",
                            "ConditionBrowseLeafName": "Pancreatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7553",
                            "ConditionBrowseLeafName": "Endocrine Gland Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12792",
                            "ConditionBrowseLeafName": "Pancreatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7552",
                            "ConditionBrowseLeafName": "Endocrine System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4387",
                            "ConditionBrowseLeafName": "Pancreatic Cancer",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC19",
                            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M2854",
                            "InterventionBrowseLeafName": "Immunomodulating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}